Amgen's MariTide combines GLP-1 receptor agonism with GIP receptor antagonism in a monthly-dosed peptide-antibody conjugate, an unusual mechanism in a market dominated by dual agonists.
View the full PeptX research peptide catalogue, or browse Retatrutide, Tirzepatide, Semaglutide, BPC-157, TB-500 and GHK-Cu.